NCT00535730View on ClinicalTrials.gov

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Herpes ZosterPneumococcal Infection
Interventions
BIOLOGICAL

Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™

0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period

BIOLOGICAL

Comparator: placebo (concomitant-vaccine matched)

Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.

BIOLOGICAL

Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00535730 - ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) | Biotech Hunter | Biotech Hunter